Omalizumab is a monoclonal antibody medication that is used in the treatment of moderate to severe allergic asthma and chronic idiopathic urticaria (hives). It works by blocking immunoglobulin E (IgE), a key player in the allergic response, thereby reducing symptoms such as wheezing, coughing, and itching. Omalizumab has been shown to be effective in improving asthma symptoms and quality of life in patients who do not respond to traditional asthma medications. It is typically administered as a subcutaneous injection every 2-4 weeks. Omalizumab is also being studied for its potential use in other allergic conditions, such as allergic rhinitis and food allergies.